Use of Immersive Virtual Reality in the Assessment and Treatment of Alzheimer's Disease: A Systematic Review.
Alzheimer’s disease
cognitive remediation
mild cognitive impairment
spatial navigation
virtual reality
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2020
2020
Historique:
pubmed:
14
4
2020
medline:
11
5
2021
entrez:
14
4
2020
Statut:
ppublish
Résumé
Immersive virtual reality (iVR) allows seamless interaction with simulated environments and is becoming an established tool in clinical research. It is unclear whether iVR is acceptable to people with Alzheimer's disease (AD) dementia or useful in their care. We explore whether iVR is a viable research tool that may aid the detection and treatment of AD. This review examines the use of iVR in people with AD or mild cognitive impairment (MCI). Medline, PsycINFO, Embase, CINAHL, and Web of Science databases were searched from inception. PRISMA guidelines were used with studies selected by at least two researchers. Nine studies were eligible for inclusion. None reported any issues with iVR tolerability in participants with MCI and AD on assessment or treatment tasks. One study demonstrated capability for detecting prodromal AD and correlated with neuroanatomical substrates. Two studies showed iVR to have high accuracy in differentiating participants with AD from controls but were not hypothesis driven or with adequate controls measures. In a small validation study and two longitudinal case studies, iVR cognitive training was positively rated but did not demonstrate reliable benefit. iVR is emerging as a viable method of assessing older adults and people with AD. Strongest benefits were seen when closely integrated with theoretical models of neurodegeneration and existing screening methods. Further randomized controlled trials integrated with clinical populations are required. This will consolidate the power of iVR for assessment of MCI and clarify treatment efficacy beyond current applications in physical rehabilitation.
Sections du résumé
BACKGROUND
Immersive virtual reality (iVR) allows seamless interaction with simulated environments and is becoming an established tool in clinical research. It is unclear whether iVR is acceptable to people with Alzheimer's disease (AD) dementia or useful in their care. We explore whether iVR is a viable research tool that may aid the detection and treatment of AD.
OBJECTIVES
This review examines the use of iVR in people with AD or mild cognitive impairment (MCI).
METHODS
Medline, PsycINFO, Embase, CINAHL, and Web of Science databases were searched from inception. PRISMA guidelines were used with studies selected by at least two researchers.
RESULTS
Nine studies were eligible for inclusion. None reported any issues with iVR tolerability in participants with MCI and AD on assessment or treatment tasks. One study demonstrated capability for detecting prodromal AD and correlated with neuroanatomical substrates. Two studies showed iVR to have high accuracy in differentiating participants with AD from controls but were not hypothesis driven or with adequate controls measures. In a small validation study and two longitudinal case studies, iVR cognitive training was positively rated but did not demonstrate reliable benefit.
CONCLUSION
iVR is emerging as a viable method of assessing older adults and people with AD. Strongest benefits were seen when closely integrated with theoretical models of neurodegeneration and existing screening methods. Further randomized controlled trials integrated with clinical populations are required. This will consolidate the power of iVR for assessment of MCI and clarify treatment efficacy beyond current applications in physical rehabilitation.
Identifiants
pubmed: 32280091
pii: JAD191218
doi: 10.3233/JAD-191218
pmc: PMC7306888
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
23-43Subventions
Organisme : Department of Health
Pays : United Kingdom
Références
Dement Geriatr Cogn Dis Extra. 2016 Jun 25;6(2):252-67
pubmed: 27489559
Gerontology. 2019;65(4):430-440
pubmed: 31108489
Aging Ment Health. 2017 May;21(5):454-467
pubmed: 26806365
PLoS One. 2016 Mar 18;11(3):e0151487
pubmed: 26990298
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Front Behav Neurosci. 2014 Mar 17;8:89
pubmed: 24672452
J Alzheimers Dis. 2013;33(2):473-81
pubmed: 22986775
Front Psychol. 2018 Nov 02;9:2120
pubmed: 30450069
PLoS One. 2017 Jul 24;12(7):e0181883
pubmed: 28738088
Hippocampus. 2015 Aug;25(8):939-51
pubmed: 25605659
Front Neurosci. 2018 Jun 15;12:408
pubmed: 29962932
Int J Psychophysiol. 2015 Mar;95(3):254-60
pubmed: 25448267
Environ Behav. 2017 Nov;49(9):1038-1065
pubmed: 29230067
Nat Rev Neurosci. 2006 Aug;7(8):663-78
pubmed: 16858394
Cochrane Database Syst Rev. 2018 Mar 01;3:CD001120
pubmed: 29493789
Physiol Behav. 2017 May 1;173:42-51
pubmed: 28137425
J Exp Neurosci. 2016 Nov 08;10:129-135
pubmed: 27840579
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Syst Rev. 2012 Feb 09;1:2
pubmed: 22587842
Med Sci Monit. 2009 Apr;15(4):CR140-50
pubmed: 19333197
Neurobiol Aging. 2012 Feb;33(2):297-303
pubmed: 20392540
J Am Med Dir Assoc. 2015 Nov 1;16(11):990-7
pubmed: 26543007
Arch Gerontol Geriatr. 2019 Jul - Aug;83:246-256
pubmed: 31102927
Geriatr Psychol Neuropsychiatr Vieil. 2017 Mar 1;15(1):65-74
pubmed: 28266343
Front Behav Neurosci. 2014 Aug 04;8:261
pubmed: 25136299
Am J Psychiatry. 2017 Apr 1;174(4):329-340
pubmed: 27838936
Ann Phys Rehabil Med. 2017 Jun;60(3):164-176
pubmed: 27017533
Behav Brain Res. 2016 Jan 1;296:384-392
pubmed: 26304718
Dementia (London). 2019 Sep 11;:1471301219868036
pubmed: 31510801
Rev Neurol (Paris). 2012 May;168(5):404-14
pubmed: 22137150
Behav Brain Res. 2016 Jul 1;307:150-8
pubmed: 27038766
Alzheimers Dement (N Y). 2019 Nov 22;5:834-850
pubmed: 31799368
Neuropsychol Rehabil. 2018 Jul;28(5):709-733
pubmed: 26480838
BMC Psychiatry. 2019 Jul 12;19(1):219
pubmed: 31299921
J Alzheimers Dis. 2016 Feb 9;52(1):77-90
pubmed: 26967209
Brain. 2019 Jun 1;142(6):1751-1766
pubmed: 31121601
Psychol Med. 2017 Oct;47(14):2393-2400
pubmed: 28325167
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Disabil Rehabil Assist Technol. 2015;10(5):421-32
pubmed: 24679074
Cyberpsychol Behav Soc Netw. 2020 Mar;23(3):165-170
pubmed: 31829729
Am J Primatol. 2014 May;76(5):496-513
pubmed: 24390812
Syst Rev. 2016 Dec 5;5(1):210
pubmed: 27919275
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Cochrane Database Syst Rev. 2017 Nov 20;11:CD008349
pubmed: 29156493
Front Aging Neurosci. 2015 May 12;7:80
pubmed: 26029101